The U.S. Food and Drug Administration has issued a stern warning to Danish pharmaceutical giant Novo Nordisk, alleging significant failures in reporting adverse effects linked to its popular weight-loss drugs Ozempic and Wegovy. In a letter dated March 5, 2026, the FDA accused the company of not disclosing "serious and unexpected" adverse drug experiences, including patient deaths, within mandated deadlines.
Serious Allegations of Non-Compliance
Dr. David Burrow, Director of the FDA's Office of Scientific Investigations, detailed in the correspondence that Novo Nordisk had systematically cancelled or rejected reports of serious adverse events that should have been submitted within 15 calendar days. The company's staff allegedly documented these incidents as unrelated to the semaglutide-based medications, despite regulatory requirements to report them regardless of perceived causality.
Specific Cases Cited
The FDA's warning letter specifically referenced three patient deaths, including one suicide, among unidentified individuals who had taken Ozempic or Wegovy. While the agency stopped short of confirming direct links between the medications and these fatalities, it emphasized that Novo Nordisk's failure to report these events constituted a violation of federal regulations designed to monitor drug safety.
Inspection Reveals Systemic Issues
The findings emerged from an inspection conducted last year at a Novo Nordisk facility in New Jersey. According to Dr. Burrow, this investigation "revealed serious violations" of adverse event reporting protocols. Although Novo Nordisk had implemented some corrective measures following the inspection, FDA officials deemed these actions "inadequate" due to insufficient detail provided about how future violations would be prevented.
Regulatory Consequences Loom
The pharmaceutical company now faces a 15-business-day deadline to address what the FDA describes as "deficiencies" in its reporting systems. Failure to comply adequately could result in regulatory action against Novo Nordisk, potentially impacting its operations and the availability of its weight-loss medications in the United States.
Company Response and Additional Scrutiny
Novo Nordisk acknowledged receiving the warning letter in a statement released earlier this week, pledging to continue addressing the FDA's observations. The company emphasized that the letter "does not make any conclusions about the quality or safety of our medicines," characterizing it as primarily seeking additional details about compliance measures.
Simultaneously, Novo Nordisk disclosed receiving another FDA warning letter following a separate inspection at its Bloomington, Indiana facility late last year. This second letter concerns compliance with Current Good Manufacturing Practice regulations, which ensure product safety, ingredient accuracy, and strength consistency.
Broader Context for Weight-Loss Drugs
Ozempic and Wegovy, both containing the active ingredient semaglutide, have become widely used by millions of Americans seeking weight management solutions. Common known side effects include nausea, vomiting, and diarrhea, but the FDA's latest action highlights concerns about potentially more severe reactions that may not be adequately tracked through existing reporting channels.
Novo Nordisk expressed confidence in its ability to "holistically and promptly address the matters outlined in each of the Warning Letters." However, the dual regulatory challenges underscore increasing scrutiny of pharmaceutical companies' post-market surveillance responsibilities as novel therapies achieve widespread adoption.
